ym 872 has been researched along with lofepramine hydrochloride in 3 studies
| Studies (ym 872) | Trials (ym 872) | Recent Studies (post-2010) (ym 872) | Studies (lofepramine hydrochloride) | Trials (lofepramine hydrochloride) | Recent Studies (post-2010) (lofepramine hydrochloride) |
|---|---|---|---|---|---|
| 41 | 0 | 5 | 17 | 0 | 1 |
| Protein | Taxonomy | ym 872 (IC50) | lofepramine hydrochloride (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.35 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.35 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.3371 | |
| Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 10 | |
| Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 0.28 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 10 | |
| P2Y purinoceptor 12 | Homo sapiens (human) | 0.35 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, N; Anraku, T; Asano, J; Shiga, F; Takano, Y; Uchiki, H | 1 |
| Anraku, T; Asano, J; Hori, W; Shiga, F; Takano, Y; Uno, T | 1 |
| Carcache, D; Kalkman, HO; Koller, M; Mattes, H | 1 |
3 other study(ies) available for ym 872 and lofepramine hydrochloride
| Article | Year |
|---|---|
Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position.
Topics: Animals; Quinoxalines; Rats; Receptors, AMPA | 2003 |
Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Imidazoles; In Vitro Techniques; Infusions, Intravenous; Neuroprotective Agents; Quinoxalines; Rats; Receptors, AMPA; Solubility; Structure-Activity Relationship | 2004 |
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Topics: Analgesics; Animals; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Protein Subunits; Receptors, AMPA | 2010 |